Health
RO LAUNCHES WEGOVY® PILL THROUGH INTEGRATION WITH NOVO NORDISK
Ro, the leading direct-to-patient healthcare company, announced today that it is working with Novo Nordisk on the nationwide launch of the new Wegovy® pill. Patients today can come to Ro.co for the easiest way to access the first and only oral GLP-1 weight loss medication at the lowest available cash pay price. Ro first integrated directly with Novo Nordisk in April 2025 and has been a key part of the manufacturer's direct-to-patient expansion to date.
About this update from Novo Nordisk A/s Class B
[{"type":"text","content":"Ro to play critical role in ensuring patients nationwide get access to first and only oral GLP-1 weight loss medication at the lowest available cash price","length":154,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, announced today that it is working with Novo Nordisk on the nationwide launch of the new Wegovy® pill. Patients today can come to Ro.co for the easiest way to access the first and only oral GLP-1 weight loss medication at the lowest available cash pay price. Ro first integrated directly with Novo Nordisk in April 2025 and has been a key part of the manufacturer's direct-to-patient expansion to date.","length":504,"tagName":"p"},{"type":"image","alt":"Meet the new GLP-1 pill on Ro","displaySize":"","headline":null,"caption":"Meet the new GLP-1 pill on Ro","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":261,"url":"https://media.zenfs.com/en/prnewswire.com/325dfc5fb14fbddad4e3c828d06e88c7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/v9jUk6Nqae4G2uj7aWIB7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ2MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/325dfc5fb14fbddad4e3c828d06e88c7","width":400,"height":261}},"href":"https://mma.prnewswire.com/media/2853814/Ro_Wegovy_Pill_Launch.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""The Wegovy pill is the most recent example of Novo Nordisk's decades-long commitment to obesity treatment. Now more than ever, it is critically important to meet the millions of people who have not previously chosen obesity medications due to administration preferences where they are," said Dave Moore, Executive Vice President, U.S. Operations for Novo Nordisk. "By tapping into Ro's vertically integrated platform, clinically eligible patients are able to seamlessly access the Wegovy® pill from diagnosis to payment to delivery, all in one place — at our lowest prices."","length":603,"tagName":"p"},{"type":"text","content":"Ro's vertically integrated platform not only provides manufacturers with immediate nationwide reach, but also the assurance that patients are receiving high-quality care. Ro recently published the first study to evaluate both the long-term weight loss and safety outcomes of trea...